Introduction  Implant-supported prostheses are often successfully used in edentulous patients. However, the incidences of peri-implant mucositis and peri-implantitis increase over time. The accumulation of pathogenic bacteria adjacent to prostheses can induce peri-implant disease. Plaque removal is recommended to prevent and manage peri-implant diseases. The purpose of this study is to compare the plaque removal efficacy of ultrasonic debridement with/without erythritol air-polishing powder around implants and bridges in patients with full-arch fixed implant-supported prostheses as well as the effects of these two methods on the rates of peri-implant mucositis and peri-implantitis, and the submucosal microbiota composition over 5 years in patients undergoing supportive periodontal therapy.

Methods and analysis  We plan to enrol 10 edentulous (maxilla and/or mandible) patients seeking full-arch fixed implant-supported prostheses. The study will use a split-mouth model in which contralateral quadrants are randomly assigned to two groups. Group 1: one contralateral quadrant of full-arch fixed implant-supported prostheses will undergo ultrasonic debridement combined with erythritol air-polishing powder. Group 2: a separate contralateral quadrant of full-arch fixed implant-supported prostheses will undergo ultrasonic debridement. The 5-year trial will involve a total of 10 re-examinations per participant. The mucosal conditions around the implants will be recorded at 6-month intervals after restoration. Peri-implant submucosal plaque will be collected at each re-examination, and the bacterial flora will be analysed by 16S ribosomal RNA gene sequencing. X-ray examinations will be conducted at 12-month intervals to evaluate the marginal bone level around implants.

Ethics and dissemination  This prospective single-centre, randomised controlled trial (PKUSSIRB-202054045) has been approved by the Ethics Committee of Stomatological School and Hospital of Peking University. Data will be registered with the International Clinical Trials Registry Platform. Additionally, we will disseminate the results via publication in scientific journals.

Trial registration number  ChiCTR-2000032431.

Strengths and limitations of this study
► This is a randomised, prospective, separately controlled trial.
► The follow-up duration is 5 years.
► We will evaluate the effects of erythritol air-polishing alone; we will not evaluate the effects of other air-polishing materials.
► The influences of local conditions will not be excluded, such as the local keratinised mucosa width and the dental arch contour.
► The study will include only generally healthy patients; it will exclude patients with systemic diseases.
Professional plaque cleaning may be performed using manual curettes, ultrasonic scalers, air polishers and lasers.

Air polishing uses abrasive powder in a stream of air to polish a microrough surface. It is an efficient mechanical debridement method for peri-implantitis treatment. Air polishing removes calculus and plaque, reduces peri-implant mucosal inflammation, and has superior efficacy to manual curettes and ultrasonic scalers. However, few studies have investigated the influence of regular air polishing on peri-implant inflammatory diseases, or the influence of peri-implant bacteria removal on full-arch fixed implant-supported prostheses. The peri-implant microbiota are influenced by the flora of the remaining teeth in patients with partial edentulism; our split-mouth randomised controlled trial will evaluate the effects of air polishing on the peri-implant microbiota.

This split-mouth randomised controlled trial is designed to compare the plaque removal efficacy of ultrasonic debridement with/without erythritol air-polishing powder around an implant and bridge in patients with full-arch fixed implant-supported prostheses as well as the effects of these two methods on the rates of peri-implant mucositis and peri-implantitis, and the submucosal microbiota composition over 5 years in patients undergoing supportive periodontal therapy.

**METHODS AND ANALYSIS**

**Trial design**

The proposed study is a 5-year randomised controlled trial. We plan to enrol 10 edentulous (maxilla and/or mandible) patients seeking full-arch fixed implant-supported prostheses. The study will use a split-mouth model in which contralateral quadrants are randomly assigned to two groups. Group 1: one contralateral quadrant of full-arch fixed implant-supported prostheses will undergo ultrasonic debridement (ultrasonic devices with polyetheretherketone-coated tips, EMS Master 750) combined with erythritol air-polishing powder (EMS Air-Flow handy V.3.0, Perio). Group 2: a separate contralateral quadrant of full-arch fixed implant-supported prostheses will undergo ultrasonic debridement. The 5-year trial will involve a total of 10 re-examinations per participant. The mucosal conditions around the implants will be recorded at 6-month intervals after restoration. Peri-implant submucosal plaque will be collected at each re-examination, and the bacterial flora will be analysed by 16s ribosomal RNA (rRNA) gene sequencing. X-ray examinations will be conducted at 12-month intervals to evaluate the marginal bone level around implants (figures 1 and 2).

**Study setting, ethical considerations and recruitment**

This prospective randomised controlled trial (PKUS-SIRB-202054045) has been approved by the Ethics Committee of Stomatology School and Hospital of Peking University, China. In addition, the study is registered in clinicaltrials.gov (ChiCTR2000032431). Participants will be recruited at Stomatology School and Hospital of Peking University. We will approach participants who meet inclusion criteria about their interest regarding this study. If interested, potential participants will be referred to our study team members who will provide a detailed description of the study procedures and invite the individual to participate. Written, informed consent will be

![Figure 1](Consolidated Standards of Reporting Trials diagram.)
obtained prior to the collection of any study data. The clinical component of the study was initiated in May 2020 at the Stomatology School and Hospital of Peking University, China.

**Patient and public involvement**

Patients and/or the public were not involved in the design, or conduct, or reporting or dissemination plans of this research. Patients meet the inclusion criteria of this study will be involved in the recruitment. The patient will assess the burden of the intervention by themselves. The outcome measures will not be informed by patients’ priorities, experiences and preferences. Data will be registered with the International Clinical Trials Registry Platform and will be disseminated to study participants.

**Eligibility**

Inclusion criteria are as follows: edentulous jaw, American Society of Anesthesiologists physical status I–II (generally healthy), good oral hygiene and good compliance and never smoker status. Exclusion criteria are age <18 years; antibiotic use in the past 3 months; if a participant uses an antibiotic in the last 3 months before recruitment, we will exclude him/her from this trial; systemic disease, including uncontrolled diabetes mellitus, cardiovascular disease, immune-related diseases, blood disorders (eg, coagulation disorders) and severe osteoporosis; long-term use of steroids, antiepileptics or bisphosphonates; infection with HIV, hepatitis B or *Treponema pallidum*; bruxism, where sleep bruxism is rhythmic (phasic) or non-rhythmic (tonic) masticatory muscle activity during sleep, which is not a movement or sleep disorder in otherwise healthy individuals, while awake bruxism is repetitive or sustained tooth contact and/or bracing or thrusting of the mandible during wakefulness, which is not a movement disorder in otherwise healthy individuals;20 21 uncontrolled infection in the area intended for implant placement or other areas; maxillofacial tumour; face–neck radiotherapy; mental illness and/or inability to provide informed consent.

**Interventions**

The treatment plan comprises placement of four to eight implants in the maxilla and/or mandible. Participants will receive the following oral hygiene instructions before entering the study: brush your teeth two times per day using a manual or electric toothbrush and fluoride toothpaste for at least 5 min, use a Waterpik at least once per day, floss under the bridge as much as possible and do not use mouthwash.

The study will use a split-mouth model in which contralateral quadrants are randomly assigned to two groups. Group 1, one contralateral quadrant of a full-arch fixed implant-supported prostheses will undergo ultrasonic debridement (ultrasonic devices with
polyethyetherketone-coated tips, EMS Master 750) combined with erythritol air-polishing powder (EMS Air-Flow handy V.3.0, Perio) at 6-month intervals. Group 2, a separate contralateral quadrant of a full-arch fixed implant-supported prostheses will undergo ultrasonic debridement at 6-month intervals. One week after each follow-up, clinical and X-ray assessments will be performed. Subsequently, the prosthesis will be removed for microbiota sampling as well as ultrasonic debridement in group 1 and ultrasonic debridement combined with air polishing in group 2. After ultrasonic debridement and air polishing, irrigation with 0.12% chlorhexidine (ie, the most effective antiplaque mouthwash) will be performed for 1 min.

### Outcome variables
The primary outcome variables will be the implant survival rate, peri-implant plaque index, peri-implant probing depth (PPD), peri-implant bleeding on probing (BOP), marginal bone loss and peri-implant submucosal bacteria. The secondary outcome variable will be peri-implant plaque staining.

### Clinical assessment
Clinical examinations will be performed at baseline (immediately after prosthetic placement) and at 6-month intervals after final prosthetic treatment placement. The following parameters will be evaluated during clinical examinations: peri-implant plaque index, BOP (0/1), suppuraton (0/1) and PPD. The peri-implant plaque index, BOP, suppuration and PPD will be evaluated at six sites per implant: mesiobuccal, buccal, distobuccal, distolingual/supragingival and PPD will be measured at the mesial and distal peri-implant marginal bone losses will be measured at the nearest millimetre using Scion Image software (Scion, Fredrick, Maryland).

The primary outcome variables will be measured as follows: periapical radiographs will be acquired immediately after final prosthetic placement, then annually thereafter. For standardisation, a parallelising technique will be used with an intramural digital system (Digora Toto, Soredex, Finland). Kodak Dental Imaging V.6.1 software (Carestream Health, Rochester, New York) will be used for radiographic analysis. The crestal bone level will be measured as the vertical distance from 2 mm below the implant-abutment interface to the most crestal part of the alveolar bone. In each group, the mean mesial and distal peri-implant marginal bone losses will be defined as the presence of bone loss (≥2 mm).

### Laboratory assessment
Sample collection
Sulcus sampling will be performed immediately before prosthetic treatment and at 6-month intervals after final prosthetic treatment placement. Antimicrobial mouthwash will not be used within 48 hours of sampling, and food will not be consumed within 1 hour of sampling. Briefly, prior to sampling, clinical sites will be isolated and dried; supramucosal plaque and calculus will be carefully removed. Submucosal plaque around a single implant will be sampled by insertion of four sterile paper points (Number 30) into the base of the sulcus or pocket for 20 s. The paper points will be placed in labelled Eppendorf tubes and frozen for transportation to the laboratory.

### Processing of microbiological samples
Detection of periodontopathic bacteria by PCR will use specific primers designed from 16s rRNA sequences. Genomic DNA will be isolated from collected samples using a TIANamp Micro DNA Kit (TianGen Biotech, Beijing, China). Detection of Porphyromonas gingivalis, Fusobacterium nucleatum spp and Prevotella intermedia will be performed by PCR in a thermal cycler (Gene Amp PCR System 2700, Foster City, California) using primers reported elsewhere. PCR products will be electrophoresed in 2% agarose gels, stained with Goldview DNA Stain (TaKaRa Biotechnology, Dalian, PR China) and examined under 300 nm ultraviolet light (Bio-Rad, USA).
Randomisation, allocation and blinding
The study will use a split-mouth model in which contralateral quadrants will be randomised by computer-generated permuted block randomisation with an allocation ratio of 1:1. Randomisation will be performed using sealed envelopes that will be opened after the final impression is recorded. Microbiota analysis will be performed in a blinded manner after assignment to interventions. Each sample will have a number associated with an allocation sequence, dental position and acquisition time. The PCR analyst will be blinded to sample identity.

Statistical methods
Statistical analysis will be conducted using Statistical Package for Social Sciences software (SPSS, V.19.0 for Macintosh, SPSS).

Clinical monitoring
Continuous variables will be described as means±SD or medians. Grade and quantitative data will be described as percentages. Age and other characteristics will be compared by independent t tests. Sex, implant survival rate, peri-implantitis rate and peri-implant mucositis will be compared by χ² tests. Clinical and X-ray indices will be compared by independent t tests. The mean percentages of sites with visible plaque, suppuration, PPD ≥5 mm and mean PPD will be computed for each participant and then averaged across participants in each group. Generalised estimating equations will be used to evaluate within-group and between-group differences. Actual p values will be reported; differences will be considered statistically significant when p<0.05.

Microbiological monitoring
The mean counts (×10⁵) of P. gingivalis, F. nucleatum spp and P. intermedia will be determined in each implant and each patient and then averaged across patients in the test and control groups. Between-group differences in microbiological parameters will be evaluated by the Wilcoxon signed rank test. Longitudinal differences in bacterial abundance will be analysed by the McNemar test. The level of statistical significance will be set at 5%.

Alpha and beta diversity analyses will be performed using Primer V.7 and QIIME V.2; these will include alpha diversity, Shannon’s diversity index of species number and distribution, Margalef’s index of numbers and Piolou’s index of evenness of distribution. The significance of differences between control and test participants will be assessed by unpaired Student’s t tests. Beta diversity analysis will include visualisation of data at multiple taxonomic levels; unweighted and weighted UniFrac distance metrics will be used to generate principal coordinates analysis plots. Analyses of similarity will be performed to determine whether microbial communities are significantly different between groups. Between-group differences in taxonomic abundance will be evaluated by White’s non-parametric test, typically with a false discovery rate cut-off of 0.005, using STAMP software.

Interim analyses
Interim statistical analyses will be performed at 1 and 3 years after prosthesis placement. The analyst will be blinded to patient allocation and will submit the results to the Data and Safety Monitoring Board. The Data and Safety Monitoring Board will announce early termination of the study if the drop-out rate exceeds 20%.

Withdrawal
Patients will be informed at the beginning of study that they have the right to withdraw from the study at any time without providing a reason. Regardless of withdrawal, the required treatment will be provided to all patients. If a participant uses an antibiotic in the 3 months before a follow-up visit, we will collect submucosa samples, perform a clinical examination, record surface roughness and conduct an X-ray examination. We will discard the data from this follow-up. However, the participant will attend subsequent visits and undergo regular periodontal maintenance. If there is no antibiotic use within 3 months of the next follow-up, we will use the data from that follow-up.

DISCUSSION
Peri-implant diseases are common but lack a standard of care. Treatment and prevention of peri-implant lesions typically involve mechanical debridement of biofilm and calculus. Mechanical cleaning of full-arch fixed implant-supported prostheses comprises the use of oral hygiene devices and professional oral hygiene interventions. Full-arch fixed implant-supported prostheses are difficult to clean because of their structural complexity, particularly around implant neck surfaces. Furthermore, bridge units exhibit a tight fit with respect to underlying mucosa and gingiva. Removal of plaque from the mucosal surface is indispensable for oral hygiene. Typical oral hygiene devices (eg, manual brushes, dental floss and interdental brushes) do not reach the mucosal surfaces of these bridge units. Bridge-optimised dental
floss, powered brushes and water flossers are recommended for this purpose. However, few patients with full-arch fixed implant-supported prostheses can maintain excellent oral hygiene in the absence of professional periodontal therapy. The proposed technique may enable submucosal biofilm removal around implants and bridges in patients with full-arch fixed implant-supported prostheses.

The major professional mechanical debridement methods are manual debridement, ultrasonic scaling with non-metal tips and air polishing. The instruments involved should be effective but not damage the prosthesis surface or disrupt the implant–soft tissue interface. Air polishing has been reported to significantly improve peri-implant mucosal health in peri-implant disease patients by reducing the plaque index and periodontal pathogen abundance. This is the scientific basis of mechanical debridement and plaque control; it could prevent peri-implant inflammatory diseases. Furthermore, air-polishing powder has good biocompatibility and causes few surface alterations. However, air polishing has an unclear influence on the anti-inflammatory effects of ultrasonic scalers in patients with full-arch fixed implant-supported prostheses.

Glycine, sodium carbonate and erythritol are the most frequently used air-polishing powders. Erythritol powder has a smaller particle size than glycine and sodium carbonate; it also exhibits low abrasiveness, a better taste, greater post-treatment biofilm regrowth inhibition and greater water solubility. Additionally, erythritol powder inhibits periodontopathogenic bacteria such as P. gingivalis. Therefore, air polishing using erythritol powder has potential for use in supragingival and submucosal biofilm management around dental implants without eliciting marked surface changes.

Individual differences influence treatment effectiveness; oral hygiene devices and plaque control affect the incidence and progression of peri-implant diseases. This split-mouth randomised controlled study involving patients with full-arch fixed implant-supported prostheses will allow the comparison of plaque removal efficacy between ultrasonic debridement plus erythritol air-polishing powder versus ultrasonic debridement alone through the exclusion of other factors.

The limited evidence available precludes conclusions concerning the efficacy of air polishing for peri-implant diseases. Further studies of combined therapies for peri-implant diseases are needed.

Author affiliations
1Department of Prosthodontics, Peking University School of Stomatology, Beijing, China
2Department of the Fourth Clinical Division, Peking University School of Stomatology, Beijing, China
3Department of Periodontology, Peking University School of Stomatology, Beijing, China
4Department of Implant dentistry, BYBO Dental Hospital Beijing, CN, Dongcheng District, Beijing, China

Acknowledgements
We are grateful to the patients who participate. We appreciate the generous support from the Peking University School and Hospital of Stomatology. We thank the data collectors, supervisors, coordinators and the patient advisers for their significant contributions to the study.

Contributors
JY, PJ, JL and ZY proposed the concept. QL and ZL designed the trial. JY and PJ drafted the manuscript. LT, JH and QL revised the sections concerning randomisation and calculation of sample size. LT and ZL reviewed and finalised the manuscript. All authors read and approved the final version of the manuscript.

Funding
This study is supported by a research grant from the New Medical Technology Program of the Stomatological Hospital of Beijing University (PKUSSNT-19811). The grant covers the ethics application and publication page fees.

Competing interests
None declared.

Patient and public involvement
Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

Patient consent for publication
Consent obtained directly from patient(s)

Provenance and peer review
Not commissioned; externally peer reviewed.

Open access
This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iD
Pingsyi Jia http://orcid.org/0000-0001-5772-4606

REFERENCES


